StockData
Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc. (BOLT) stock

BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/305% above fair value
$5.65−0.15 (-2.59%)

Close on Nov 17, 2026Market cap $10.88MP/E –Yield –

Bolt Biotherapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Bolt Biotherapeutics

Bolt Biotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Bolt Biotherapeutics figures

See a number that looks wrong?